{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:48:13Z","timestamp":1794023293213,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clinre.2023.102177","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T22:00:57Z","timestamp":1689285657000},"page":"102177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-5471","authenticated-orcid":false,"given":"Marine","family":"Perrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Mouawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Gueguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Thom\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2023.102177_bib0001","doi-asserted-by":"crossref","first-page":"e490s","DOI":"10.6061\/clinics\/2018\/e490s","article-title":"Carcinoid syndrome: update on the pathophysiology and treatment","volume":"73","author":"Rubin de Celis Ferrari","year":"2018","journal-title":"Clin Sao Paulo Braz"},{"key":"10.1016\/j.clinre.2023.102177_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MED.0000000000000376","article-title":"Carcinoid-syndrome: recent advances, current status and controversies","volume":"25","author":"Ito","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.clinre.2023.102177_bib0003","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinre.2023.102177_bib0004","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinre.2023.102177_bib0005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"key":"10.1016\/j.clinre.2023.102177_bib0006","doi-asserted-by":"crossref","first-page":"e13390","DOI":"10.1097\/MD.0000000000013390","article-title":"Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: a survey study","volume":"97","author":"Halperin","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clinre.2023.102177_bib0007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000499049","article-title":"Systemic Treatment Options for Carcinoid Syndrome: a Systematic Review","volume":"96","author":"Wolin","year":"2019","journal-title":"Oncology"},{"key":"10.1016\/j.clinre.2023.102177_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819828217","article-title":"Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review","volume":"10","author":"Grande","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.clinre.2023.102177_bib0009","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s40273-018-0656-z","article-title":"Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors","volume":"36","author":"Shen","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinre.2023.102177_bib0010","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1245\/s10434-017-5986-0","article-title":"Patterns and Drivers of Costs for Neuroendocrine Tumor Care: a Comparative Population-Based Analysis","volume":"24","author":"Hallet","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clinre.2023.102177_bib0011","first-page":"e12983","article-title":"Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study","volume":"28","author":"Les\u00e9n","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.clinre.2023.102177_bib0012","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1634\/theoncologist.2017-0149","article-title":"Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients","volume":"22","author":"Shen","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clinre.2023.102177_bib0013","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.2217\/fon-2018-0129","article-title":"Economic analysis of inadequate symptom control in carcinoid syndrome in the United States","volume":"14","author":"Burton","year":"2018","journal-title":"Future Oncol Lond Engl"},{"key":"10.1016\/j.clinre.2023.102177_bib0014","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40273-020-00896-5","article-title":"A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome","volume":"38","author":"Fust","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinre.2023.102177_bib0015","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.3748\/wjg.v22.i6.2118","article-title":"Healthcare and economic impact of diarrhea in patients with carcinoid syndrome","volume":"22","author":"Broder","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2023.102177_bib0016","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.3748\/wjg.v25.i47.6857","article-title":"Direct costs of carcinoid syndrome diarrhea among adults in the United States","volume":"25","author":"Dasari","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2023.102177_bib0017","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1080\/00365521.2018.1531653","article-title":"Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study","volume":"53","author":"Les\u00e9n","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 4","key":"10.1016\/j.clinre.2023.102177_bib0018","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d'information interr\u00e9gimes de l'Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.clinre.2023.102177_bib0019","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinre.2023.102177_bib0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","article-title":"French health insurance databases: what interest for medical research?","volume":"36","author":"Moulis","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.clinre.2023.102177_bib0021","first-page":"1068","article-title":"ELECT Study Group *. Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"10.1016\/j.clinre.2023.102177_bib0022","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clinre.2023.102177_bib0023","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clinre.2023.102177_bib0024","first-page":"326","article-title":"Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses","volume":"35","author":"Ferolla","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinre.2023.102177_bib0025","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cam4.435","article-title":"Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors","volume":"4","author":"Al-Efraij","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.clinre.2023.102177_bib0026","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clinre.2023.102177_bib0027","article-title":"Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)","author":"de Mestier","year":"2020","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10.1016\/j.clinre.2023.102177_bib0028","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.therap.2018.09.076","article-title":"The value of a health insurance database to conduct pharmacoepidemiological studies in oncology","volume":"74","author":"Conte","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.clinre.2023.102177_bib0029","doi-asserted-by":"crossref","unstructured":"Harrow B., Fagnani F., Nevoret C., Truong-Thanh X.M., de Z\u00e9licourt M., de Mestier L. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: a Nationwide French Retrospective Cohort Study in the Real- Life Setting. Adv Ther 2022;39(4):1754\u201371.","DOI":"10.1007\/s12325-022-02060-1"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221074012300102X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221074012300102X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:35:16Z","timestamp":1761896116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221074012300102X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S221074012300102X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102177","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102177"}}